use
adjuv
key
element
promot
vaccin
effect
stimul
immun
system
acceler
prolong
enhanc
antigenspecif
immun
respons
even
use
combin
weak
vaccin
antigen
adjuv
use
vaccin
sinc
earli
centuri
follow
year
research
us
alum
remain
sole
fdaapprov
adjuv
gener
use
vaccin
howev
adjuv
licens
use
around
world
new
adjuv
approv
unit
state
sinc
recent
european
head
medicin
agenc
licens
adjuv
use
defin
vaccin
respect
use
combin
aluminum
hydroxid
monophosphoryl
lipid
mpl
formul
also
licens
fda
octob
prevent
cervic
cancer
caus
human
papillomaviru
type
adjuv
import
guid
type
adapt
respons
induc
vaccin
effect
incom
infect
develop
novel
adjuv
stimul
discret
subset
immun
cell
particular
cytotox
tlymphocyt
ctl
requir
unleash
full
potenti
new
vaccin
immunotherapi
strategi
although
tremend
progress
made
develop
mani
vaccin
platform
includ
dnabas
vaccin
recombin
subunit
vaccin
virus
conjug
absenc
safe
effect
adjuv
imped
clinic
develop
new
gener
vaccin
interest
develop
new
adjuv
increas
significantli
past
decad
highlight
follow
issu
inabl
tradit
approach
develop
success
vaccin
difficult
organ
hiv
hcv
emerg
epidem
outbreak
new
infecti
diseas
high
mortal
especi
caus
seriou
threat
public
health
socioeconom
stabil
worldwid
eg
sar
ebola
west
nile
dengu
pandem
flu
nvcjd
reemerg
old
infect
like
tuberculosi
continu
spread
antibioticresist
bacteria
increas
threat
bioterror
therefor
molecular
design
potent
adjuv
vaccin
would
enhanc
antigen
uptak
vivo
potenti
also
simplifi
adjuv
requir
would
highli
desir
mani
report
show
helminthderiv
molecul
potent
regulatori
stimulatori
effect
immun
system
mammalian
host
review
molecul
shown
contain
pathogen
associ
molecular
pattern
bind
endocyticpattern
recognit
receptor
antigen
present
cell
apc
three
helminth
product
also
report
act
adjuv
experiment
vaccin
model
protein
secret
adult
nippostrongylu
brasiliensi
ne
induc
strong
respons
mice
immun
hen
egg
lysozym
ne
activ
matur
dendrit
cell
dc
select
upregul
togeth
product
block
respons
manner
consist
gener
vivo
similarli
lactonfucopentaos
iii
lnfpiii
carbohydr
found
surfac
egg
human
parasit
schistosoma
mansoni
act
adjuv
human
serum
albumin
inject
intranas
subcutan
intraperitoneali
mice
function
innat
promot
via
action
murin
dc
abil
drive
matur
shown
depend
signal
via
tolllik
receptor
final
coadminist
inactiv
antiinfluenza
vaccin
young
age
mice
aa
synthet
peptid
taenia
crassicep
cysticerci
induc
increas
level
antiinfluenza
antibodi
age
mice
infect
reduc
local
inflamm
accompani
influenza
vaccin
favor
viru
clearanc
infect
young
age
mice
recombin
onchocerca
volvulu
activationassoci
shown
novel
protein
adjuv
increas
specif
immun
respons
mice
humor
cellular
respons
recombin
protein
peptidebas
antigen
formul
aqueou
mixtur
previous
suggest
effect
probabl
attain
cellular
activ
apc
dendrit
cell
via
adjuv
abl
induc
balanc
antibodi
protein
polypeptid
small
peptid
antigen
rbd
hbsag
also
promot
put
respons
base
pronounc
induct
antibodi
respons
andor
significantli
upregul
product
cytokin
includ
abil
augment
antibodi
respons
demonstr
studi
use
three
commerci
inactiv
vaccin
hemorrhag
fever
renal
syndrom
flu
rabi
moreov
novel
recombin
configur
fuse
copi
highli
conserv
extracellular
domain
influenza
protein
sequenc
abl
induc
high
level
igg
provid
strong
crossprotect
lethal
challeng
virus
differ
clade
clade
clade
studi
demonstr
adjuvant
sequenti
vaccin
mice
also
confirm
abil
potent
innat
adjuv
nhp
evalu
adjuv
activ
mice
immun
sarscov
rrbd
presenc
absenc
alum
cpg
comparison
previous
report
could
effect
induc
mix
immun
respons
rs
rrbd
immun
mice
shown
figur
titer
rbdspecif
igg
antibodi
increas
first
second
boost
immun
sera
mice
immun
rrbd
plu
significantli
higher
mice
immun
rrbd
alon
igg
respons
mice
vaccin
rrbd
presenc
alum
significantli
higher
second
boost
respons
significantli
higher
first
boost
antirrbd
igg
respons
significantli
higher
presenc
cpg
second
boost
compar
mice
vaccin
rrbd
vs
notabl
augment
igg
antibodi
respons
rrbd
almost
time
higher
alum
vaccin
group
vs
time
higher
cpg
vaccin
group
vs
alreadi
first
boost
comparison
alum
induc
rrbd
antibodi
respons
second
boost
reveal
similar
level
vs
twofold
higher
level
vs
well
ten
time
higher
level
vs
endpoint
titer
vaccin
group
comparison
cpg
induc
rrbd
antibodi
respons
second
boost
reveal
fold
increas
vs
fold
increas
vs
fold
increas
vs
endpoint
titer
adjuvantrrbd
model
perform
differ
depend
adjuv
eg
skew
respons
alum
mix
respons
cpg
predomin
antibodi
taken
account
result
support
previou
studi
show
induc
balanc
antibodi
respons
bia
toward
skew
antibodi
respons
adjuv
use
bystand
antigen
alum
cpg
studi
mlp
plu
tdm
adjuv
evalu
whether
induc
igg
antibodi
could
neutral
infect
sarscov
vitro
fig
test
antisera
postsecond
boost
immun
found
mice
immun
rrbd
presenc
contain
high
titer
neutral
antibodi
infect
sarscov
pseudoviru
significantli
differ
neutral
antibodi
found
sera
mice
immun
rrbd
plu
alum
adjuv
subclass
immunoglobulin
induc
immun
indirect
measur
rel
contribut
cytokin
cytokin
studi
data
cba
analys
show
level
cytokin
secret
significantli
higher
mice
immun
alum
immun
rrbd
alon
tabl
induc
product
type
proinflammatori
cytokin
extent
alum
well
cytokin
signific
recal
induct
cytokin
rrbd
data
shown
notabl
respons
rrbd
formul
cpg
comparison
domin
diminish
respons
found
variat
individu
mice
low
therefor
confid
result
obtain
use
pool
spleen
good
represent
would
outcom
use
individu
mice
distinct
previou
studi
respons
two
rbdspecif
peptid
cell
epitop
cell
epitop
tabl
interestingli
cytokin
level
cultur
supernat
murin
splenocyt
stimul
either
similar
produc
stimul
full
length
rrbd
mice
vaccin
thu
confirm
abil
elicit
rbdspecif
cellular
respons
test
vaccin
formul
use
mous
model
first
immun
mice
rrbd
sarscov
evalu
efficaci
adjuvant
sequenti
vaccin
use
three
influenza
virus
nymc
viru
model
antigen
balbc
mice
mice
ten
week
immun
rrbd
presenc
immun
influenza
virus
absenc
presenc
yeast
express
mice
previous
immun
rrbd
presenc
endpoint
total
antibodi
titer
time
prime
second
vaccin
shown
tabl
similar
humor
immun
respons
influenza
virus
induc
mice
vaccin
previous
rrbd
plu
adjuv
administ
pb
moreov
higher
group
got
sequenti
vaccin
vs
antiha
antibodi
respons
much
higher
mice
immun
vaccin
presenc
adjuv
immun
absenc
adjuv
vs
vs
level
igg
isotyp
respons
mice
flu
vaccin
formul
statist
higher
mice
immun
adjuv
p
fig
signific
differ
respons
flu
vaccin
given
mice
mice
previous
immun
anoth
vaccin
rrbd
adjuvant
evalu
rhesu
macaqu
immun
model
use
rrbd
target
antigen
sarscov
vaccin
shown
tabl
nhp
vaccin
rrbd
protein
plu
n
n
cpg
n
adjuv
develop
rbdspecif
igg
antibodi
respons
increas
antibodi
level
boost
rbdspecif
antibodi
detect
preimmun
sera
vaccin
rhesu
macaqu
rhesu
macaqu
inject
rbdpb
control
n
immun
rrbd
plu
optim
quantiti
cpg
adjuv
use
vaccin
studi
effect
induct
rbdspecif
antibodi
endpoint
igg
titer
third
boost
although
limit
pilot
experi
use
two
concentr
e
coli
express
adjuv
formul
two
four
time
amount
use
mous
model
experi
clearli
show
immun
adjuv
exhibit
dosedepend
efficaci
induct
rbdspecif
antibodi
two
macaqu
per
group
endpoint
igg
titer
notabl
antibodi
respons
titer
adjuv
lower
nhp
might
expect
base
data
mice
rang
immun
macaqu
monkey
first
boost
second
boost
third
boost
although
antirbd
endpoint
tier
much
higher
nhp
immun
cpg
differ
titer
less
promin
sera
rhesu
macaqu
vaccin
rrbdadjuv
formul
effect
neutral
infect
sar
pseudoviru
cell
express
receptor
valu
shown
figur
sera
macaqu
immun
rrbd
protein
plu
induc
slightli
higher
titer
neutral
antibodi
group
vs
macaqu
immun
cpg
higher
titer
vitro
studi
describ
show
mice
immun
strong
cytokin
product
ex
vivo
stimul
rrbd
protein
rbdspecif
peptid
notabl
signific
respons
obtain
nhp
immun
rrbd
presenc
cpg
ex
vivo
pbmc
stimul
rrbd
tabl
cytokin
respons
similar
regardless
amount
use
adjuv
secret
cytokin
neglig
vaccin
remain
effect
mean
prevent
erad
infecti
diseas
ongo
effort
appli
activ
immun
approach
prevent
treat
autoimmun
diseas
cancer
adjuv
potenti
antigenspecif
immun
respons
key
element
vaccin
effect
adjuv
broadli
separ
two
class
base
princip
mechan
action
vaccin
deliveri
system
immunostimul
vaccin
deliveri
system
gener
particul
function
mainli
target
associ
antigen
apc
eg
emuls
microparticl
iscom
liposom
immunostimulatori
adjuv
contain
residu
recogn
receptor
apc
tlr
play
import
role
innat
recognit
pathogen
dc
thu
directli
activ
innat
immun
respons
adjuv
regard
effect
mean
adjuvantantigen
complex
target
apc
adjuv
target
multipl
innat
immun
receptor
may
prove
effect
adjuv
may
induc
differ
arm
immun
respons
host
number
microbi
product
includ
bacteri
lp
peptidoglycan
dsrna
muramyl
peptid
cpg
flagellin
microbi
protein
shown
act
vaccin
adjuv
immunomodul
could
skew
acquir
immun
respons
toward
immun
respons
adjuv
also
classifi
accord
capac
stimul
either
innat
adapt
immun
base
signific
differ
cellular
receptor
mechan
action
previous
note
alum
adjuv
licens
us
gener
use
human
yet
alum
effect
stimul
andor
cytotox
cell
respons
number
pathogen
therefor
limit
applic
particular
newgener
vaccin
adjuv
develop
clinic
test
includ
mpl
saponin
deriv
cpg
flagellin
combin
adjuv
one
major
concern
regard
use
immunostimulatori
adjuv
human
possibl
increas
risk
autoimmun
diseas
due
target
pattern
recognit
receptor
adjuv
howev
recombin
adjuv
studi
correspond
secret
filari
protein
present
antigen
volvulu
expos
infect
individu
africa
evid
show
secret
filari
protein
could
induc
autoimmun
diseas
infect
patient
thu
exclud
concern
polar
immun
achiev
addit
complet
freund
adjuv
cpg
dna
antigen
hand
antibodi
respons
induc
alum
incomplet
freund
adjuv
indic
increas
rel
howev
situat
respons
requir
protect
choic
one
regimen
anoth
might
counter
effect
led
addit
research
altern
adjuv
adjuv
combin
promot
balanc
mix
respons
present
studi
clearli
demonstr
could
effect
induc
mix
rbd
haspecif
antibodi
associ
respons
use
adjuv
recombin
subunit
vaccin
addit
commerci
flu
vaccin
fluvirin
use
dose
recommend
human
use
sinc
adjuv
protein
potenti
process
present
immun
system
subsequ
induc
antibodi
self
therefor
concern
might
rais
whether
preexist
antibodi
may
suppress
adjuvant
use
subsequ
vaccin
formul
previous
demonstr
antibodi
respons
adjuv
hinder
develop
ova
rs
rrbd
antigenspecif
antibodi
respons
boost
case
respons
presenc
elev
presenc
mpltmp
alum
adjuv
present
result
confirm
antibodi
induc
adjuv
impact
abil
induc
immun
respons
bystand
antigen
use
adjuv
sequenti
vaccin
two
vaccin
model
system
use
rbd
sarscov
spike
protein
commerci
influenza
viru
ha
vaccin
compris
three
viru
strain
even
though
high
level
antibodi
present
sera
mice
administr
second
vaccin
adjuvant
retain
efficaci
similar
obtain
use
adjuv
first
vaccin
immun
mice
tabl
figur
differ
igg
titer
observ
two
vaccin
group
mice
preimmun
pb
thu
confirm
preexist
antibodi
induc
previous
administr
vaccin
signific
effect
adjuvant
formul
subsequ
vaccin
notabl
immun
nhp
induc
high
titer
antiselfantibodi
reason
yet
clear
futur
studi
need
valid
even
reason
low
antibodi
respons
adjuv
impact
subsequ
use
adjuv
vaccin
also
nhp
pilot
immunogen
studi
nhp
provid
us
extrem
valuabl
proof
princip
inform
outbr
primat
model
firstli
advers
reaction
observ
site
immun
indic
safeti
adjuv
secondli
use
two
concentr
adjuv
rrbd
vaccin
antigen
abl
induc
three
immun
high
titer
neutral
antibodi
much
exceed
need
protect
sarscov
infect
vivo
moreov
studi
shown
abl
support
induct
function
antibodi
pathogen
nhp
thu
clear
way
futur
develop
human
vaccin
well
thu
pilot
nhp
studi
definit
step
demonstr
relev
human
vaccin
formul
even
though
studi
need
find
optim
amount
adjuv
vaccin
formul
specifi
put
start
adjuv
dose
futur
clinic
trial
vaccin
interestingli
see
augment
recal
rbd
specif
cellular
respons
except
therefor
futur
studi
need
valid
adjuvant
primat
point
abil
augment
desir
type
cellular
respons
associ
protect
immun
possibl
pathogen
durat
immun
potenti
establish
cell
memori
summari
present
studi
advanc
confid
protein
adjuv
develop
human
use
particularli
strong
function
balanc
antibodi
respons
need
pathogen
importantli
use
immun
mice
previous
immun
mice
ha
vaccin
express
yeast
function
yeast
express
adjuv
support
futur
develop
scalabl
process
downstream
manufactur
includ
develop
seri
critic
biochem
biophys
assay
inprocess
releas
stabil
test
result
highyield
reproduc
product
process
stabl
product
highli
potent
stimul
desir
antibodi
cellular
respons
coadminist
vaccin
antigen
nhp
analys
futur
clinic
trial
human
anim
protocol
approv
institut
anim
care
use
committe
new
york
blood
center
mice
protocol
tulan
nation
primat
research
center
nhp
protocol
tulan
nation
primat
research
center
tnprc
usdainspect
associ
assess
accredit
laboratori
anim
care
intern
aaalac
approv
facil
anim
welfar
assur
file
offic
laboratori
anim
welfar
anim
studi
carri
strict
accord
recommend
american
veterinari
medic
associ
avma
guidelin
approv
protocol
anim
handl
delic
treatment
done
extrem
care
profession
avoid
unnecessari
discomfort
anim
forti
two
femal
balbc
mice
age
week
six
purposebr
adult
male
indianorigin
rhesu
macaqu
age
year
use
studi
anim
hous
environment
condit
met
applic
standard
blood
collect
retroorbit
mice
femor
vein
use
sarstedt
smonovett
system
nhp
anim
anesthet
use
ketamin
mlkg
im
amelior
suffer
anim
blood
draw
immun
nhp
protocol
also
includ
full
cbc
profil
taken
blood
draw
result
fall
within
normal
level
bodi
weight
frequent
monitor
physic
examin
perform
regularli
attend
veterinarian
protein
express
histidinetag
protein
escherichia
coli
purifi
previous
describ
purifi
test
neg
limulu
amoebocyt
lysat
assay
quantit
lp
test
cambrex
bioscienc
show
purifi
contain
endotoxin
unit
per
milligram
protein
pg
endotoxinmg
consid
lpsfree
stock
addit
express
yeast
yeast
codon
optim
cdna
sequenc
without
region
encod
ntermin
signal
peptid
clone
pichia
express
vector
invitrogen
use
ecori
xbai
restrict
site
recombin
plasmid
linear
saci
digest
transform
pichia
pastori
strain
describ
previous
posit
transform
screen
zeocinresist
ypd
plate
highest
express
clone
select
scale
cultur
express
cmyc
tag
cterminu
induc
methanol
scale
liter
ferment
describ
previous
purifi
ferment
cultur
sp
sepharos
fast
flow
exchang
chromatographi
describ
previous
briefli
ferment
supernat
filter
membran
ph
adjust
ad
glacial
acet
acid
posit
charg
captur
onto
cation
sp
sepharos
ff
column
elut
mm
sodium
acet
ph
contain
mm
nacl
elut
pool
purifi
buffer
exchang
use
gel
filtrat
chromatographi
sephadex
fine
pb
ph
product
test
adjuvant
mice
use
ova
model
antigen
previous
describ
establish
yeastexpress
per
mous
effect
per
mice
e
coli
express
elicit
two
immun
end
point
antiova
igg
titer
data
shown
thu
e
coli
yeast
express
optim
quantiti
use
intermitt
assur
mice
vaccin
subcutan
rrbd
protein
purifi
cultur
supernat
transfect
human
embryon
kidney
celllin
atcc
va
accord
previous
describ
protocol
use
protein
mix
aqueou
solut
e
coliexpress
optim
quantiti
adjuv
control
immun
mice
rrbd
mix
imject
alum
mgml
aluminum
mgml
magnesium
hydroxid
thermo
scientif
dilut
vaccin
antigen
total
volum
per
mous
rrbd
mix
invivogen
san
diego
ca
total
volum
per
mous
mice
immun
rrbd
pb
use
neg
control
mice
boost
twice
week
apart
rrbd
protein
pb
imject
alum
cpg
mice
bled
retroorbit
anaesthesia
prior
immun
day
post
inject
sera
store
test
adjuvant
sequenti
vaccin
model
immun
intramuscularli
mice
mice
previous
immun
commerci
flu
vaccin
contain
influenza
viru
hemagglutinin
ha
follow
virus
nymc
viru
fluvirin
novarti
immun
done
presenc
absenc
yeastexpress
optim
quantiti
mice
boost
dose
vaccin
three
week
later
mice
bled
prior
immun
day
post
immun
describ
sera
store
rhesu
macaqu
vaccin
subcutan
rrbd
protein
either
n
n
e
coliexpress
cpgcissodn
n
donat
dynavax
technolog
corpor
berkeley
ca
pb
n
boost
dose
interv
macaqu
bled
immun
day
postimmun
sera
collect
serolog
test
pbmc
purifi
vitro
assay
baselin
bleed
also
provid
elisa
use
detect
specif
antibodi
respons
induc
vaccin
mous
nhp
briefli
micro
titer
plate
costar
coat
rrbd
overnight
plate
block
nonfat
milk
pbstween
h
wash
plate
six
time
pbst
serial
dilut
sera
bind
buffer
nonfat
milk
pbst
ad
well
duplic
incub
h
bound
antibodi
detect
hrpconjug
goat
antimous
igg
molecular
probesinvitrogen
dilut
mous
antimonkey
igghrp
clone
southern
biotech
dilut
bind
buffer
incub
h
plate
wash
tmb
substrat
kpl
ad
reaction
stop
addit
n
absorb
nm
measur
use
spectramax
molecular
devic
sunnyval
ca
end
point
titer
defin
highest
dilut
give
measur
cutoff
valu
repres
valu
mean
optic
densiti
od
plu
standard
deviat
sd
normal
mous
serum
sampl
test
dilut
preble
normal
nhp
serum
sampl
also
test
dilut
neutral
assay
sar
pseudoviru
infect
perform
previous
describ
brief
plasmid
dna
encod
sarscov
spike
protein
plasmid
dna
encod
envdefect
luciferaseexpress
genom
cotransfect
cell
attc
ga
cultur
supernat
contain
sar
pseudoviru
collect
h
use
singlecycl
infect
vitro
sar
pseudoviru
incub
presenc
absenc
serial
dilut
antisera
vaccin
mice
nhp
h
subsequ
antiseraviru
mixtur
ad
cell
express
sar
receptor
angiotensinconvert
enzym
plate
infect
allow
proceed
h
follow
lyse
infect
cell
use
cell
lysi
buffer
includ
luciferas
kit
promega
aliquot
cell
lysat
transfer
costar
flatbottom
luminomet
plate
corn
costar
follow
addit
luciferas
substrat
promega
rel
light
unit
determin
immedi
ultra
luminomet
tecan
neutral
sar
pseudoviru
present
neutral
antibodi
titer
cytokin
assay
use
estim
correspond
cytokin
product
ex
vivo
splenocyt
vaccin
mice
briefli
splenocyt
harvest
immun
mice
resuspend
rpmi
medium
invitrogen
carlsbad
ca
supplement
fb
hyclon
laboratori
inc
mm
lglutamin
mm
hepe
antibioticantimycot
invitrogen
carlsbad
ca
cell
plate
cell
ubottom
cultur
plate
vitro
stimul
rrbd
sarscov
rbdspecif
cell
epitop
cell
epitop
peptid
concentr
predetermin
optim
cell
stimul
without
pma
ngml
plu
ionomycin
posit
neg
control
respect
plate
incub
h
secret
cytokin
quantifi
cultur
supernat
use
mous
bd
cytometr
bead
array
kit
bd
bioscienc
accord
manufactur
protocol
theoret
limit
detect
data
pgml
pgml
pgml
pgml
pgml
pgml
pgml
detect
cytokin
product
vaccin
nhp
done
use
similar
protocol
modif
pbmc
isol
follow
ficollhypaqu
densiti
gradient
sigma
singlecel
suspens
stimul
cell
rrbd
peptid
pma
ngml
plu
ionomycin
posit
control
cultur
media
alon
neg
control
cell
stimul
day
cytokin
quantifi
use
nonhuman
primat
bd
cytometr
bead
array
kit
bd
bioscienc
accord
manufactur
protocol
result
express
mean
sem
data
analyz
use
graphpad
version
window
graphpad
softwar
unpair
twotail
student
test
mannwhitney
test
use
compar
mean
differ
group
oneway
anova
bonferroni
posttest
consid
appropri
multipl
comparison
p
valu
less
consid
signific
